Core Concepts
Antigen tests should expand beyond COVID.
Abstract
The content discusses the evolution of lateral flow tests (LFTs) from their limited use before the pandemic to their widespread adoption during COVID-19. It emphasizes the need to expand the role of LFTs to detect various diseases beyond COVID, highlighting the potential benefits and challenges associated with this expansion.
Pre-Pandemic Familiarity with LFTs
- LFTs were not widely known before the pandemic.
- COVID-19 necessitated large-scale testing.
- PCR remains the gold standard for COVID diagnosis.
Current Status of LFTs
- FDA authorizes 32 rapid antigen tests for home use.
- Experts advocate for expanding LFTs to detect other diseases.
- Calls for a global network of LFT research hubs.
Medical Community Support
- Clinicians endorse increased availability of LFTs.
- LFTs offer quick results and ease of use.
- Potential for more LFTs in various healthcare settings.
How LFTs Work
- LFTs target antigens, antibodies, and nucleic acids.
- Process of LFTs explained.
- Global market outlook for LFTs.
Pros and Cons of LFTs
- LFTs provide rapid results but lower accuracy than PCR.
- Challenges and strengths of LFTs discussed.
- Importance of understanding the best use cases for different technologies.
FDA's Perspective
- FDA evaluates LFTs based on individual indications.
- Different pathways for LFT review.
- Recommendations for LFT performance.
Future of LFTs
- Predictions on increased self-testing and seeking care.
- Vision for testing technology evolution.
- Funding challenges post-COVID for LFT research.
Stats
By 2030, the lateral flow assays market is predicted to rise to $14.1 billion.
COVID antigen LFTs have a sensitivity ranging from 34.1% to 88.1%.
The lateral flow assays market was estimated at $9.4 billion in 2022.
Quotes
"Rapid antigen tests are critical, made a big difference in the pandemic, and will be used increasingly for many other applications in the years ahead." - Eric J. Topol
"It's a much smarter pathway, gives better outcomes for the patient, is much quicker and at much less cost. And it frees up time for doctors." - Jeremy Stackawitz